Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gadolinium-enhanced brain lesions in multiple sclerosis relapse, Lesiones cerebrales captantes de gadolinio en el brote de los pacientes con esclerosis múltiple

  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Presas Rodríguez, Sílvia|||0000-0001-8545-2476
  • Rovira, Alex|||0000-0002-2132-6750
  • Capellades, Jaume|||0000-0002-1417-4496
  • Massuet-Vilamajó, Anna
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Tintoré, Mar|||0000-0001-9999-5359
  • Brieva Ruiz, Luis|||0000-0002-5871-6189
  • Moral, Esther
  • Cano-Orgaz, Antonio Tomás
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Batlle-Nadal, Jaume
  • Carmona, Olga|||0000-0002-5957-0046
  • Gea, Mireia
  • Hervas-Garcia, Jose Vicente|||0000-0002-1132-0291
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
Objective: To study the clinico-radiological paradox in multiple sclerosis (MS) relapse by analyzing the number and location of gadolinium-enhanced (Gd+) lesions on brain MRI before methylprednisolone (MP) treatment. Methods: We analyzed brain MRI from 90 relapsed MS patients in two Phase IV multicenter double-blind randomized clinical trials that showed the noninferiority of different routes and doses of MP administration. A 1.5- or 3-T brain MRI was performed at baseline before MP treatment and within 15 days of symptom onset. The number and location of Gd+ lesions were analyzed. Associations were studied using univariate analysis. Results: Sixty-two percent of patients had at least 1 Gd+ brain lesion; the median number was 1 (interquartile range 0-4), and 41% of patients had 2 or more lesions. The most frequent location of Gd+ lesions was subcortical (41.4%). Gd+ brain lesions were found in 71.4% of patients with brainstem-cerebellum symptoms, 57.1% with spinal cord symptoms and 55.5% with optic neuritis (ON). Thirty percent of patients with brain symptoms did not have Gd+ lesions, and only 43.6% of patients had symptomatic Gd+ lesions. The univariate analysis showed a negative correlation between age and the number of Gd+ lesions (p = 0.002). Conclusion: Most patients with relapse showed several Gd+ lesions on brain MRI, even when the clinical manifestation was outside of the brain. Our findings illustrate the clinico-radiological paradox in MS relapse and support the value of brain MRI in this scenario., Objetivo: Estudiar la paradoja clínico-radiológica en el brote de la esclerosis múltiple (EM) mediante el análisis de lesiones captantes de gadolinio (Gd+) en la RM cerebral antes del tratamiento con metilprednisolona (MP). Métodos: Analizamos la RM cerebral basal de 90 pacientes con EM en brote de 2 ensayos clínicos aleatorizados multicéntricos fase IV que demostraron la no inferioridad de diferentes vías y dosis de MP, realizadas antes del tratamiento con MP y en los 15 días siguientes a la aparición de los síntomas. Se analizaron el número y la localización de las lesiones Gd+. Se estudiaron las asociaciones mediante análisis univariado. Resultados: El 62% de los pacientes tenía al menos una lesión Gd+ cerebral y el 41% de los pacientes tenía 2 o más lesiones. La localización más frecuente fue la subcortical (41,4%). Se encontraron lesiones Gd+ cerebrales en el 71,4% de los pacientes con síntomas de tronco cerebral o cerebelo, en el 57,1% con síntomas medulares y en el 55,5% con neuritis óptica. El 30% de los pacientes con síntomas cerebrales no tenían lesiones Gd+ y sólo el 4,.6% de los pacientes tenían lesiones Gd+ sintomáticas. El análisis univariante mostró una correlación negativa entre la edad y el número de lesiones Gd+ (p = 0,002). Conclusiones: La mayoría de los pacientes en brote mostraron varias lesiones Gd+ en la RM cerebral, incluso cuando la manifestación clínica fue medular u óptica. Nuestros hallazgos ilustran la paradoja clínico-radiológica en el brote de la EM y apoyan el valor de la RM cerebral en este escenario.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

  • Martín-Aguilar, Lorena|||0000-0002-1553-2224
  • Lleixà, Cinta|||0000-0002-9971-0584
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Martinez-Martinez, Laura|||0000-0003-0126-158X
  • Diaz-Manera, Jordi|||0000-0003-2941-7988
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Rajabally, Yusuf
  • Scotton, Sangeeta
  • Jacobs, Bart C.|||0000-0002-8985-2458
  • Baars, Adája Elisabeth|||0000-0001-7842-0871
  • Cortese, Andrea
  • Vegezzi, Elisa|||0000-0001-8776-6831
  • Höftberger, Romana|||0000-0002-5769-1100
  • Zimprich, Fritz|||0000-0002-6998-5480
  • Roesler, Cornelia
  • Nobile-Orazio, Eduardo|||0000-0003-2624-8138
  • Liberatore, Giuseppe|||0000-0003-2666-1678
  • Hiew, Fu Liong|||0000-0002-4708-3734
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Carvajal, Alejandra
  • Piñar Morales, Raquel|||0000-0003-3490-4932
  • Usón-Martín, Mercedes
  • Albertí, Olalla
  • López Pérez, María Ángeles
  • Márquez, Fabian
  • Pardo-Fernández, Julio
  • Muñoz-Delgado, Laura|||0000-0002-8818-1824
  • Cabrera-Serrano, Macarena|||0000-0003-3109-6095
  • Ortiz-Castellon, Nicolau|||0000-0001-9544-2642
  • Bartolomé, Manuel
  • Duman, Özgür
  • Bril, Vera
  • Segura-Chávez, Darwin
  • Pitarokoili, Kalliopi
  • Steen, Claudia
  • Illa, Isabel|||0000-0002-2186-2684
  • Querol, Luis|||0000-0002-4289-8264
Background and ObjectivesTo study the clinical and laboratory features of antineurofascin-155 (NF155)-positive autoimmune nodopathy (AN).MethodsPatients with anti-NF155 antibodies detected on routine immunologic testing were included. Clinical characteristics, treatment response, and functional scales (modified Rankin Scale [mRS] and Inflammatory Rasch-built Overall Disability Scale [I-RODS]) were retrospectively collected at baseline and at the follow-up. Autoantibody and neurofilament light (NfL) chain levels were analyzed at baseline and at the follow-up.ResultsForty NF155+ patients with AN were included. Mean age at onset was 42.4 years. Patients presented with a progressive (75%), sensory motor (87.5%), and symmetric distal-predominant weakness in upper (97.2%) and lower extremities (94.5%), with tremor and ataxia (75%). Patients received a median of 3 (2-4) different treatments in 46 months of median follow-up. Response to IV immunoglobulin (86.8%) or steroids (72.2%) was poor in most patients, whereas 77.3% responded to rituximab. HLA-DRB1*15 was detected in 91.3% of patients. IgG4 anti-NF155 antibodies were predominant in all patients; anti-NF155 titers correlated with mRS within the same patient (r = 0.41, p = 0.004). Serum NfL (sNfL) levels were higher in anti-NF155+ AN than in healthy controls (36.47 vs 7.56 pg/mL, p < 0.001) and correlated with anti-NF155 titers (r = 0.43, p = 0.001), with I-RODS at baseline (r = -0.88, p < 0.001) and with maximum I-RODS achieved (r = -0.58, p = 0.01). Anti-NF155 titers and sNfL levels decreased in all rituximab-treated patients.DiscussionAnti-NF155 AN presents a distinct clinical profile and good response to rituximab. Autoantibody titers and sNfL are useful to monitor disease status in these patients. The use of untagged-NF155 plasmids minimizes the detection of false anti-NF155+ cases.Classification of EvidenceThis study provides Class IV evidence that anti-NF155 antibodies associate with a specific phenotype and response to rituximab.